Last reviewed · How we verify
AEGR-733 and ezetimibe
AEGR-733 and ezetimibe is a Small molecule drug developed by Aegerion Pharmaceuticals, Inc.. It is currently in Phase 2 development.
At a glance
| Generic name | AEGR-733 and ezetimibe |
|---|---|
| Sponsor | Aegerion Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS (PHASE2)
- Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents (PHASE2)
- The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AEGR-733 and ezetimibe CI brief — competitive landscape report
- AEGR-733 and ezetimibe updates RSS · CI watch RSS
- Aegerion Pharmaceuticals, Inc. portfolio CI
Frequently asked questions about AEGR-733 and ezetimibe
What is AEGR-733 and ezetimibe?
AEGR-733 and ezetimibe is a Small molecule drug developed by Aegerion Pharmaceuticals, Inc..
Who makes AEGR-733 and ezetimibe?
AEGR-733 and ezetimibe is developed by Aegerion Pharmaceuticals, Inc. (see full Aegerion Pharmaceuticals, Inc. pipeline at /company/aegerion-pharmaceuticals-inc).
What development phase is AEGR-733 and ezetimibe in?
AEGR-733 and ezetimibe is in Phase 2.
Related
- Manufacturer: Aegerion Pharmaceuticals, Inc. — full pipeline
- Compare: AEGR-733 and ezetimibe vs similar drugs
- Pricing: AEGR-733 and ezetimibe cost, discount & access